See more : China City Infrastructure Group Limited (2349.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Lantern Pharma Inc. (LTRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantern Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- mPhase Technologies, Inc. (XDSL) Income Statement Analysis – Financial Results
- Beijing Energy International Holding Co., Ltd. (0686.HK) Income Statement Analysis – Financial Results
- Nichidenbo Corporation (3090.TW) Income Statement Analysis – Financial Results
- Ackermans & Van Haaren NV (ACKB.BR) Income Statement Analysis – Financial Results
- Molten Metals Corp (MOLT.CN) Income Statement Analysis – Financial Results
Lantern Pharma Inc. (LTRN)
About Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| Gross Profit | -174.84K | -154.68K | -97.42K | -3.39K | -1.63K | 2.54K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.89M | 8.60M | 7.57M | 2.24M | 953.19K | 572.10K |
| General & Administrative | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Other Expenses | 0.00 | -31.55K | 160.55K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Cost & Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Interest Income | 765.39K | 204.36K | 67.93K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 204.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| EBITDA | -15.79M | -14.42M | -12.27M | -5.90M | -2.43M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.88M | -14.43M | -12.59M | -5.91M | -2.43M | -1.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.92M | 172.81K | 228.48K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -15.96M | -14.26M | -12.36M | -5.91M | -2.43M | -1.73M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -172.81K | -67.93K | -202.91K | -5.00 | 2.54K |
| Net Income | -15.96M | -14.09M | -12.30M | -5.91M | -2.43M | -1.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| EPS Diluted | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| Weighted Avg Shares Out | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
| Weighted Avg Shares Out (Dil) | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
The 3 Most Undervalued AI Penny Stocks to Buy Now: August 2023
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
Lantern Pharma Inc. (LTRN) Q2 2023 Earnings Call Transcript
3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True
3 AI Stocks You'll Regret Not Buying Soon
7 AI Stocks to Buy Under $5 in August 2023
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
3 AI Stocks to Buy Under $10 in August 2023
7 AI Penny Stocks that Could Hit $5 Soon
Lantern Pharma to Participate and Present at Multiple Upcoming Conferences
Source: https://incomestatements.info
Category: Stock Reports